Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neurobiology of Opioid Dependence: 1 - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00000192
Recruitment Status : Withdrawn
First Posted : September 21, 1999
Last Update Posted : August 7, 2015
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Yale University

Brief Summary:
The purpose of this study is to evaluate the effects of lamotrigine on naloxone-precipitated opiate withdrawal.

Condition or disease Intervention/treatment Phase
Opioid-Related Disorders Drug: Lamotrigine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Masking: Double
Primary Purpose: Treatment
Official Title: Neurobiology of Opioid Dependence: 1
Study Start Date : January 1993
Actual Primary Completion Date : January 1998
Actual Study Completion Date : January 1998

Resource links provided by the National Library of Medicine

Drug Information available for: Lamotrigine




Primary Outcome Measures :
  1. Behavioral, subjective, measures of naloxone-precipitated opiate withdrawal
  2. Phsyiological, neuroendocrine measures of naloxone-precipitated opiate withdrawal


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000192


Locations
Layout table for location information
United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
National Institute on Drug Abuse (NIDA)
Investigators
Layout table for investigator information
Principal Investigator: Marc I Rosen, M.D. VA Connecticut Healthcare System
Publications:
Layout table for additonal information
Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT00000192    
Other Study ID Numbers: NIDA-00191-1
K20DA000191 ( U.S. NIH Grant/Contract )
K20-00191-1
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: August 7, 2015
Last Verified: August 2015
Keywords provided by Yale University:
opioid disorders
Additional relevant MeSH terms:
Layout table for MeSH terms
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Lamotrigine
Anticonvulsants
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Sodium Channel Blockers